https://www.selleckchem.com/products/fg-4592.html
ivity assay for TTP diagnosis and follow-up. Thrombopoietin receptor agonists (TPO-RAs) are used to treat primary immune thrombocytopenia (ITP). Some patients have discontinued treatment while maintaining a hemostatic platelet count. To develop expert consensus on when it is appropriate to consider tapering TPO-RAs in ITP, how to taper patients off therapy, how to monitor patients after discontinuation, and how to restart therapy. We used a RAND/UCLA modified Delphi panel method. Ratings were completed independently by each expert befor
Like
Comment
Share
